<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Arch Pharm Pract</journal-id>
      <journal-id journal-id-type="publisher-id">archivepp.com</journal-id>
      <journal-id journal-id-type="publisher-id">Arch Pharm Pract</journal-id>
      <journal-title-group>
        <journal-title>Archives of Pharmacy Practice</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2320-5210</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">archivepp.com-1267</article-id>
      <article-id pub-id-type="doi">10.51847/SgQOuL1Mc5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Digital Pharmacy Services and Unequal Access to Medicines: An Integrative Review of Equity Consequences</article-title>
      </title-group>
                    <contrib-group>
                      <contrib contrib-type="author">
              <name>
                <surname>O&#039;Leary</surname>
                <given-names>James</given-names>
              </name>
                              <xref rid="aff1" ref-type="aff">1</xref>
                                                            <xref rid="cor1" ref-type="corresp" />
                          </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Dunne</surname>
                <given-names>Aisling</given-names>
              </name>
                              <xref rid="aff1" ref-type="aff">1</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>O&#039;Brien</surname>
                <given-names>Sean</given-names>
              </name>
                              <xref rid="aff2" ref-type="aff">2</xref>
                                        </contrib>
                  </contrib-group>
                  <aff id="aff1">
            <label>1</label>Department of Pharmacy Equity and Digital Access, School of Pharmacy, Trinity College Dublin, Dublin, Ireland.
          </aff>
                  <aff id="aff2">
            <label>2</label>Department of Health Equity and Digital Pharmacy, School of Pharmacy, University College Cork, Cork, Ireland.
          </aff>
                          <author-notes>
            <corresp id="cor1">
              <bold>Address for correspondence:</bold> Prof. Wael Abu Dayyih, Department of
              Pharmaceutical Chemistry, Faculty of Pharmacy, Mutah University, Al-Karak 61710, Jordan.
                          </corresp>
          </author-notes>
                    <pub-date pub-type="epub">
        <day>30</day>
        <month>12</month>
        <year>2025</year>
      </pub-date>
      <volume>16</volume>
      <issue>4</issue>
      <fpage>73</fpage>
      <lpage>81</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Archives of Pharmacy Practice
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>Digital pharmacy services increasingly mediate how patients obtain medicines, advice, and follow-up. Their expansion may reduce distance and time barriers, but benefits are not distributed uniformly because connectivity, affordability, literacy, language, disability, trust, and organizational capacity shape use. To integrate empirical, theoretical, and policy-relevant evidence on how digital pharmacy services influence unequal access to medicines, who benefits, who encounters barriers, and which contextual conditions reduce or amplify inequity. A transparent integrative review used a protocol-defined search, eligibility criteria, record-level screening, source-type-sensitive appraisal, structured extraction, comparative data reduction, and thematic synthesis. Access was treated as multidimensional rather than equivalent to service availability. Evidence was compared across digital access, affordability, reach, literacy, language, disability, usability, geography, organizational capacity, data representation, and algorithmic processes.

Digital pharmacy can extend service reach, support continuity, and reduce travel or scheduling burdens when infrastructure, accessible design, human assistance, and implementation capacity are adequate. The same services can intensify exclusion when participation requires reliable connectivity, suitable devices, digital or health literacy, dominant-language fluency, accessible interfaces, trust, or institutional support. Evidence concerning algorithmic equity remained less mature than evidence concerning telepharmacy and digital access barriers. Reported benefits were therefore conditional, context-dependent, and not interchangeable with equitable access. Digital pharmacy is neither inherently equity-promoting nor inherently exclusionary. Equity consequences arise from interactions among service design, patient resources, organizational arrangements, and data practices. Evaluation should examine who can enter, use, understand, trust, and meaningfully benefit from the service, while retaining nondigital alternatives and escalation routes.</p>
      </abstract>
      <kwd-group>
                <kwd>Integrative review</kwd>
                <kwd>Digital pharmacy</kwd>
                <kwd>Artificial intelligence</kwd>
                <kwd>Pharmacy practice</kwd>
                <kwd>Medication safety</kwd>
                <kwd>Evidence synthesis</kwd>
              </kwd-group>
    </article-meta>
  </front>
</article>